Skip to main content
Premium Trial:

Request an Annual Quote

MDS Acquires Blueshift Biotechnologies

NEW YORK (GenomeWeb News) – MDS said today that its MDS Analytical Technologies unit has acquired cell imaging products firm Blueshift Biotechnologies for $13 million.
 
Sunnyvale, Calif.-based Blueshift makes the IsoCyte benchtop instrument, which performs rapid image analysis of large populations of cells in a microtiter plate whole-well format. According to Toronto-based MDS, Blueshift has placed 14 of the IsoCyte instruments with academic, biotech, and pharmaceutical customers.
 
“This acquisition fills a gap in our current product portfolio, allowing us to offer our pharmaceutical research customers fast and simple cellular analysis with a line of instrumentation that images the whole well at true high throughput screening rates,” Andy Boorn, president of MDS Analytcial Technologies, said in a statement.
 
The firms did not disclose Blueshift’s annual revenues.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.